Eosinophilic Gastroenteritis

  1. Overview
  2. Classification — Klein's Three Layers
  3. Epidemiology and Atopic Background
  4. Pathophysiology — IL-5 and IL-13 Eosinophil Recruitment
  5. Clinical Presentation
  6. Diagnosis — Endoscopy, Biopsy, and Exclusions
  7. Differential Diagnosis
  8. Treatment — Steroids, Diet, and Emerging Biologics
  9. Prognosis and Long-Term Course
  10. Practical Guidance for Patients
  11. Research Papers
  12. Connections
  13. Featured Videos

Overview

Eosinophilic gastroenteritis (EGE) is a rare inflammatory disorder in which eosinophils — white blood cells normally absent from most of the gastrointestinal tract — infiltrate the wall of the stomach and small intestine in large numbers. It belongs to the family of eosinophilic gastrointestinal diseases (EGIDs), which includes eosinophilic esophagitis (EoE, esophagus), eosinophilic gastritis (EoG, stomach alone), eosinophilic enteritis (small intestine alone), and eosinophilic colitis (colon). EGE most often involves more than one of these segments simultaneously.

EGE is estimated to affect roughly 1 in 100,000 people in Western countries, though this figure likely underestimates true prevalence because the disease is frequently misdiagnosed as irritable bowel syndrome, Crohn's disease, or food intolerance before the correct diagnosis is established. It can occur at any age — from infancy through late adulthood — with peaks in early adulthood (20s–30s) and in childhood.

The unifying theme across EGIDs is a Th2-driven immune response to food antigens (and, in some patients, aeroallergens), which recruits eosinophils into gut tissue via key cytokines — particularly IL-5, IL-13, and the eosinophil-specific chemoattractant eotaxin-3 (CCL26). Unlike the esophagus, the stomach and intestine normally contain small numbers of resident eosinophils (particularly in the right colon), so distinguishing pathological eosinophilia from normal variation requires careful biopsy interpretation.

Because EGE is rare and biologically heterogeneous, clinical trials are scarce. Most treatment evidence comes from case series and small cohort studies. This makes personalized, specialist-guided care essential.

Back to Table of Contents

Classification — Klein's Three Layers

The most widely used classification system for EGE was proposed by Klein and colleagues in 1970 and divides the disease by which layer of the bowel wall is predominantly infiltrated by eosinophils. Each layer produces a strikingly different clinical syndrome.

1. Mucosal EGE (most common, approximately 60% of cases)

Eosinophils infiltrate the innermost lining of the gut — the mucosa and lamina propria. This causes villous atrophy (damage to the absorptive villi of the small intestine), crypt hyperplasia, and disruption of enterocyte function. The result is a malabsorption syndrome that closely mimics celiac disease: chronic diarrhea (sometimes with steatorrhea in severe cases), protein-losing enteropathy (hypoalbuminemia, edema), iron deficiency anemia, and weight loss. Food is not absorbed normally, and proteins leak out of the inflamed mucosa.

2. Muscularis EGE (10–30% of cases)

Eosinophilic infiltration extends into the muscular wall of the bowel (muscularis propria). This causes bowel wall thickening, rigidity, and dysmotility — the gut cannot contract and relax properly. Patients develop a picture of mechanical or functional bowel obstruction: severe cramping abdominal pain, nausea, postprandial vomiting, and abdominal distension. On CT imaging, affected segments show diffuse wall thickening. Rarely, this layer of disease leads to obstruction severe enough to require surgical intervention.

3. Serosal EGE (approximately 10% of cases)

Eosinophils infiltrate the outermost layer of the bowel (serosa) and spill into the peritoneal cavity. The hallmark is eosinophilic ascites — accumulation of peritoneal fluid that is rich in eosinophils (typically >10% eosinophils among ascitic fluid cells). This is the rarest but most dramatic presentation of EGE. Patients present with abdominal distension, a shifting dullness on percussion, and confirmed ascites on imaging. Analysis of the ascitic fluid distinguishes eosinophilic ascites from ascites caused by cirrhosis, malignancy, or infection. Peripheral blood eosinophilia is usually very high in serosal EGE. The serosal form responds well to corticosteroids but can recur.

These three layers can occur in isolation or in combination. Pure mucosal disease is by far the most common presentation encountered in clinical practice.

Back to Table of Contents

Epidemiology and Atopic Background

EGE is genuinely rare. Estimates based on claims databases and referral center registries suggest a prevalence of approximately 5–8 per 100,000 people in the United States, though rigorous population-level data are lacking. The disease appears to be more common in Western, industrialized countries, consistent with the "hygiene hypothesis" that reduced early-life microbial exposure promotes atopic disease.

Age and sex: EGE can occur at any age. Children are affected, with EGE presenting as failure to thrive, protein-losing enteropathy, or protein-wasting diarrhea in infants and toddlers. In adults, the peak is in the 3rd and 4th decades. Unlike EoE (which is strongly male-predominant), EGE has a more equal sex distribution, with some series showing a slight female predominance.

Atopic background: Approximately 50–70% of EGE patients have a history of atopic disease — asthma, allergic rhinitis, atopic dermatitis, or food allergy. This atopic association is one of the strongest clues that food antigens and Th2 immune dysregulation drive the disease. Patients often have elevated serum IgE and peripheral blood eosinophilia. A personal or family history of allergy should prompt consideration of EGE in a patient with unexplained GI symptoms.

Food allergen associations: Unlike IgE-mediated food allergy (in which standard allergy testing reliably identifies triggers), EGE triggering foods are identified through empirical elimination and reintroduction with endoscopic monitoring. Common implicated foods overlap with EoE triggers: dairy, wheat, egg, soy, and seafood. Systematic food elimination can induce remission in many patients, although the evidence base is thinner than for EoE.

Seasonal variation in symptom severity — with worsening during high-pollen seasons — has been reported in some patients, paralleling observations in EoE and suggesting that aeroallergens (not just food) contribute to eosinophil recruitment in the gut.

Back to Table of Contents

Pathophysiology — IL-5 and IL-13 Eosinophil Recruitment

The central immune abnormality in EGE is a Th2-polarized adaptive immune response that drives eosinophil production, recruitment, and tissue residence in the stomach and intestine. The same cytokine axes that drive EoE operate in EGE, but the target tissue differs.

IL-5 — the master eosinophil cytokine: IL-5, produced by Th2 CD4+ T cells, ILC2 innate lymphoid cells, and mast cells, is the primary driver of eosinophil differentiation in the bone marrow and release into the bloodstream. Elevated IL-5 in EGE accounts for the prominent peripheral blood eosinophilia seen in most patients. Anti-IL-5 therapies (mepolizumab, benralizumab) have been used in hypereosinophilic syndrome (HES) — a systemic eosinophilic disorder that can overlap with EGE — with proven efficacy, providing proof of concept that this pathway is the key therapeutic target.

IL-13 and eotaxin-3 (CCL26): IL-13, another Th2 cytokine, acts on gastrointestinal epithelial cells to upregulate eotaxin-3, the key tissue chemoattractant for eosinophils. IL-13 also disrupts epithelial barrier function, allowing food antigens to penetrate the mucosa and perpetuate the inflammatory cycle. In EoE, IL-13 blockade with dupilumab (anti-IL-4Rα, which also blocks IL-4) is FDA-approved; trials in broader EGID populations are underway.

IgE-independent mechanisms: Most food-triggered EGE is not IgE-mediated — standard allergy skin tests and serum food-specific IgE levels do not reliably identify trigger foods in EGE. Instead, the underlying mechanism appears to involve T-cell-mediated delayed hypersensitivity, non-IgE-dependent mast cell activation, and potentially ILC2-driven type 2 inflammation. This is why patch testing (which detects T-cell-mediated reactions) may be more informative than skin-prick tests for food triggers in some patients.

Normal eosinophil distribution in the gut: A key diagnostic challenge is that small numbers of eosinophils are normally present in the stomach, small intestine, and particularly the right colon. The diagnosis of EGE requires pathologically elevated counts — generally accepted thresholds are ≥30 eosinophils per high-power field (eos/hpf) in the stomach and ≥50 eos/hpf in the small intestine, with no universally agreed standard. Context matters: the same count that is diagnostic in an inflamed-appearing stomach is less meaningful in the normal-appearing right colon.

Back to Table of Contents

Clinical Presentation

EGE produces non-specific symptoms that vary enormously depending on the layer of bowel wall affected (Klein classification), the segment of GI tract involved, and disease severity. There is no single symptom or sign that is pathognomonic for EGE — the diagnosis requires biopsy. Patients often go years before the correct diagnosis is made.

Most common presenting symptoms:

Signs of malabsorption (mucosal type):

Obstruction (muscularis type): Episodic or persistent nausea, vomiting, cramping, constipation, and abdominal distension. May mimic small bowel obstruction from adhesions or Crohn's disease stricture.

Eosinophilic ascites (serosal type): Painless progressive abdominal distension, shifting dullness, and confirmed ascites on imaging. May be the sole presenting feature or accompany mucosal or muscularis disease. Paracentesis reveals a striking eosinophil-rich fluid.

Laboratory clues:

Back to Table of Contents

Diagnosis — Endoscopy, Biopsy, and Exclusions

There is no single diagnostic test for EGE. The diagnosis rests on three pillars: compatible symptoms + histological eosinophilia on biopsy + exclusion of other causes of gut eosinophilia. The diagnostic workup is systematic and requires specialist gastroenterology involvement.

Step 1: Exclude secondary causes of gastrointestinal eosinophilia

Several conditions cause gut eosinophilia that can mimic EGE and must be actively excluded before attributing eosinophilia to a primary EGID:

Step 2: Endoscopy with multiple biopsies

Upper endoscopy (esophagogastroduodenoscopy, EGD) is the primary diagnostic tool. Key principles:

Step 3: Histology — eosinophil counts

Eosinophil counts per high-power field (eos/hpf) at the peak infiltrated area are the diagnostic measure. General guiding thresholds (no universal consensus exists):

Step 4: Ascitic fluid analysis (serosal EGE)

In patients with ascites of uncertain cause, paracentesis reveals: eosinophil-rich fluid (>10% of nucleated cells are eosinophils), typically exudative or transudative, with low SAAG (serum-ascites albumin gradient), no bacteria on culture, and no malignant cells. This picture is essentially diagnostic of serosal EGE in the right clinical context.

Imaging:

Allergy testing: Standard skin-prick testing and serum food-specific IgE are of limited utility for identifying EGE trigger foods (non-IgE mechanism). Patch testing (atopy patch test, APT) may identify T-cell-mediated food triggers in some patients and is used in conjunction with dietitian-guided elimination.

Back to Table of Contents

Differential Diagnosis

EGE must be distinguished from a range of conditions that produce overlapping symptoms and, in many cases, overlapping histological eosinophilia. The differential is broad because gut eosinophilia is a histological finding, not a diagnosis in itself.

Back to Table of Contents

Treatment — Steroids, Diet, and Emerging Biologics

EGE treatment is based on a small evidence base of case series and expert consensus. The primary goals are symptom relief, induction and maintenance of histological remission, correction of nutritional deficiencies, and avoidance of long-term steroid toxicity.

1. Corticosteroids — the mainstay of therapy

Systemic corticosteroids (prednisolone/prednisone 20–40 mg/day orally for 2–4 weeks) produce dramatic responses in the vast majority of patients — approximately 90% or more experience significant symptom relief and histological improvement within 2–4 weeks. This rapid steroid responsiveness is one of the most distinctive features of EGE and helps confirm the diagnosis. The main limitation is a high relapse rate when steroids are tapered: most patients relapse within weeks to months, making many steroid-dependent.

In serosal EGE with eosinophilic ascites, steroids are equally effective — ascites typically resolves within days to weeks of starting prednisolone.

Budesonide (oral; enteric-coated formulations designed for small bowel release) is increasingly used as a steroid-sparing alternative, particularly for mucosal small bowel disease. Its high first-pass hepatic metabolism (90%) reduces systemic side effects compared to prednisolone. Experience is from case series, not randomized trials.

2. Dietary therapy

Based on the evidence from EoE and the known atopic/food-trigger pathophysiology of EGE, dietary elimination is a rational first-line or adjunctive strategy:

Dietary therapy is best implemented with a GI dietitian experienced in elimination protocols and nutritional monitoring.

3. Mast cell stabilizers and antihistamines (steroid-sparing)

4. Emerging biologics

5. Supportive care and nutritional management

6. Surgical management (rare)

Surgery is occasionally required for muscularis EGE presenting with complete or near-complete bowel obstruction not responding rapidly to steroids. Laparoscopic adhesiolysis, stricturoplasty, or limited bowel resection may be needed. Ascites in serosal EGE can be drained for comfort but systemic steroid treatment is the definitive approach.

Back to Table of Contents

Prognosis and Long-Term Course

EGE follows a relapsing-remitting course in most patients. Complete sustained remission off all treatment is uncommon; the majority of patients require long-term maintenance therapy or dietary management to prevent relapse. The natural history in untreated patients is generally one of persistent or worsening symptoms, but severe complications such as perforation, major hemorrhage, or malignant transformation are uncommon.

Steroid dependence: Most patients (60–80%) relapse when corticosteroids are tapered below a threshold dose or discontinued, making steroid dependence the central management challenge. Long-term steroid use carries well-known risks: osteoporosis, glucose intolerance, adrenal suppression, cataracts, and susceptibility to infection. This drives the need for steroid-sparing strategies (dietary therapy, budesonide, biological agents).

Nutritional complications: Patients with mucosal EGE may develop lasting nutritional consequences from prolonged protein-losing enteropathy — low bone density, muscle wasting, and micronutrient depletion. Careful dietitian follow-up and periodic laboratory monitoring (albumin, ferritin, vitamin D, B12, zinc) are important parts of long-term care.

Malignancy risk: There is no established increased risk of gastrointestinal cancer in EGE (unlike inflammatory bowel disease), and eosinophilic infiltration itself has not been shown to be premalignant. Long-term surveillance endoscopy intervals are guided by clinical need rather than oncological surveillance.

Quality of life: EGE profoundly impairs quality of life through dietary restriction, meal-related anxiety, unpredictable diarrhea or pain, and the physical and psychological burden of steroid dependence. Validated patient-reported outcome measures specific to EGID are under development. Psychological support and patient advocacy organizations (e.g., the American Partnership for Eosinophilic Disorders, APFED) are valuable resources for patients and families.

Back to Table of Contents

Practical Guidance for Patients

Living with eosinophilic gastroenteritis can feel overwhelming, particularly because the disease is rare, many general practitioners are unfamiliar with it, and treatment decisions are individualized. Here are practical points to help you navigate the diagnosis and management.

Getting to the right specialist: EGE requires care from a gastroenterologist experienced with eosinophilic disorders, ideally at an academic or referral center. Some centers have dedicated EGID clinics. A GI dietitian who specializes in elimination diets and malabsorption is an essential partner. If you have concurrent atopic disease (asthma, eczema, food allergy), allergist/immunologist involvement adds value.

Understanding your subtype: Ask your doctor which Klein layer is primarily involved in your case — mucosal, muscularis, or serosal. This directly predicts your symptoms and informs treatment priorities (malabsorption workup for mucosal; obstruction management for muscularis; paracentesis and drainage for serosal).

Food elimination is worth trying: Even without positive allergy testing, a structured dietary elimination trial (starting with the six most common triggers) can induce remission in some patients. This requires a gastroenterology follow-up endoscopy to confirm histological response — not just symptom improvement — before concluding that the diet is working. Work with a dietitian to ensure nutritional adequacy during elimination, particularly calcium, vitamin D, and iron.

Steroids are a tool, not a solution: Prednisone works fast and reliably but is not a long-term answer for most people. The goal of the treatment plan is to control the disease using the minimum effective dose of steroids while exploring dietary and biological options to reduce or eliminate steroid dependence. Bone protection (calcium, vitamin D, possibly bisphosphonates for long-term steroid users) is important.

Symptom diary: Tracking what you eat, your symptoms, and peripheral blood eosinophil counts (if your doctor monitors them) helps identify patterns and triggers. Bring this diary to follow-up appointments.

Patient support: The American Partnership for Eosinophilic Disorders (APFED) at apfed.org and the Campaign Urging Research for Eosinophilic Disease (CURED) Foundation provide patient education, support communities, and research updates. EGE is rare enough that participating in a patient registry or clinical trial — if eligible — contributes meaningfully to the field.

Back to Table of Contents

Research Papers

  1. Klein NC, Hargrove RL, Sleisenger MH, Jeffries GH. Eosinophilic gastroenteritis. Medicine (Baltimore). 1970;49(4):299–319. PMID 5426180
  2. Talley NJ, Shorter RG, Phillips SF, Zinsmeister AR. Eosinophilic gastroenteritis: a clinicopathological study of patients with disease of the mucosa, muscle layer, and subserosal tissues. Gut. 1990;31(1):54–58. PMID 2318432
  3. Caldwell JM, Collins MH, Stucke EM, et al. Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome. J Allergy Clin Immunol. 2014;134(5):1114–1124. PMID 25042987
  4. Furuta GT, Atkins FD, Lee NA, Lee JJ. Changing roles of eosinophils in health and disease. Ann Allergy Asthma Immunol. 2014;113(1):3–8. PMID 24768647
  5. Pesek RD, Reed CC, Muir AB, et al. Increasing rates of diagnosis, substantial co-occurrence, and variable treatment patterns of eosinophilic gastritis, gastroenteritis, and colitis based on 10-year data across a multicenter consortium. Am J Gastroenterol. 2019;114(6):984–994. PMID 31135468
  6. Dellon ES, Gonsalves N, Hirano I, et al. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis. Am J Gastroenterol. 2013;108(5):679–692. PMID 23567357
  7. Uppal V, Kreiger P, Kutsch E. Eosinophilic gastroenteritis and colitis: a comprehensive review. Clin Rev Allergy Immunol. 2016;50(2):175–188. PMID 26037027
  8. Gonsalves N, Yang GY, Doerfler B, et al. Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. Gastroenterology. 2012;142(7):1451–1459. PMID 22391333
  9. Lwin T, Melton SD, Genta RM. Eosinophilic gastritis: histopathological characterization and quantification of the normal gastric eosinophil content. Mod Pathol. 2011;24(4):556–563. PMID 21169987
  10. Straumann A, Bauer M, Fischer B, Blaser K, Simon HU. Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J Allergy Clin Immunol. 2001;108(6):954–961. PMID 11742273
  11. van Rhijn BD, Verheij J, Smout AJ, Bredenoord AJ. Rapidly increasing incidence of eosinophilic esophagitis in a large cohort. Neurogastroenterol Motil. 2013;25(1):47–52. PMID 23216583
  12. Sunkara T, Rawla P, Yarlagadda KS, Gaduputi V. Eosinophilic gastroenteritis: diagnosis and clinical perspectives. Clin Exp Gastroenterol. 2019;12:239–253. PMID 31239735

Back to Table of Contents

Connections

Back to Table of Contents